logo

Obseva Sa (OBSV)



Trade OBSV now with
  Date
  Headline
3/5/2021 1:09:05 AM ObsEva FY Net Loss $83.0 Mln Or $1.67/Shr Vs Loss $108.8 Mln Or $2.49/Shr Last Year
1/11/2021 1:57:17 AM ObsEva Says EMA Validates Yselty MAA For Uterine Fibroids; US NDA Planned For H1'21
1/4/2021 1:05:27 AM ObsEva Appoints David Renas As CFO And Member Of Company's Executive Committee
11/24/2020 1:12:00 AM ObsEva Submits Marketing Authorization Application To EMA For YSELTY For Women With Uterine Fibroids
11/16/2020 1:06:30 AM ObsEva Reports Positive Topline Results Of PROLONG Proof-of-Concept Trial Of Ebopiprant (OBE022) For Preterm Labor
7/6/2020 1:16:07 AM ObsEva Announces Positive Results From Two Phase 3 Studies, PRIMROSE 1 And 2, Of Yselty
7/1/2020 1:06:38 AM ObsEva: Yuyuan Submits Pre-IND Meeting Request For Nolasiban To Center For Drug Evaluation At The Chinese NMPA